

Citations

- Aziz, Q., Giamberardino, M. A., Barke, A., Korwisi, B., Baranowski, A. P., Wesselmann, U., Rief, W., & Treede, R.-D. (2019). The IASP classification of chronic pain for ICD-11: chronic secondary visceral pain. In *Pain* (Vol. 160, Issue 1, pp. 69–76). Ovid Technologies (Wolters Kluwer Health).
<https://doi.org/10.1097/j.pain.0000000000001362>
- Hah, J. M., Aivaliotis, V. I., Hettie, G., Pirrotta, L. X., Mackey, S. C., & Nguyen, L. A. (2022). Whole Body Pain Distribution and Risk Factors for Widespread Pain Among Patients Presenting with Abdominal Pain: A Retrospective Cohort Study. In *Pain and Therapy* (Vol. 11, Issue 2, pp. 683–699). Springer Science and Business Media LLC.
<https://doi.org/10.1007/s40122-022-00382-0>
- Hetta, D. F., Mahran, A. M., & Kamal, E. E. (2018). Pulsed Radiofrequency Treatment for Chronic Post-Surgical Orchialgia: A Double-Blind, Sham-Controlled, Randomized Trial: Three-Month Results. *Pain physician*, 21(2), 199–205.
- Hunter, C., Davé, N., Diwan, S., & Deer, T. (2012). Neuromodulation of Pelvic Visceral Pain: Review of the Literature and Case Series of Potential Novel Targets for Treatment. In *Pain Practice* (Vol. 13, Issue 1, pp. 3–17). Wiley. <https://doi.org/10.1111/j.1533-2500.2012.00558.x>
- Imamura, M., Scott, N. W., Wallace, S. A., Ogah, J. A., Ford, A. A., Dubos, Y. A., & Brazzelli, M. (2020). Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis. In *Cochrane Database of Systematic Reviews* (Vol. 2020, Issue 7). Wiley. <https://doi.org/10.1002/14651858.cd013325.pub2>
- Kalkan, Ü., & Daniilidis, A. (2019). Laparoscopic Diagnosis and Treatment of Obturator Nerve Entrapment Because of a Deep Infiltrating Endometriotic Nodule: A Case Report. In *Journal of Minimally Invasive Gynecology* (Vol. 26, Issue 4, pp. 766–769). Elsevier BV. <https://doi.org/10.1016/j.jmig.2018.09.776>
- Lee SC, Rha D, Kim H, *et al.* Ultrasound-Guided Injection of the Intrapelvic Portion of the Obturator Internus in a Cadaver Model *Regional Anesthesia & Pain Medicine* 2014;**39**:347-350.
- Ploteau, S., Perrouin-Verbe, M. A., Labat, J. J., Riant, T., Levesque, A., & Robert, R. (2017). Anatomical Variants of the Pudendal Nerve Observed during a Transgluteal Surgical Approach in a Population of Patients with Pudendal Neuralgia. *Pain physician*, 20(1), E137–E143.
- Ploteau, S., Salaud, C., Hamel, A., & Robert, R. (2017). Entrapment of the posterior femoral cutaneous nerve and its inferior cluneal branches: anatomical basis of surgery for inferior cluneal neuralgia. In *Surgical and Radiologic Anatomy* (Vol. 39, Issue 8, pp. 859–863). Springer Science and Business Media LLC. <https://doi.org/10.1007/s00276-017-1825-z>
- Possover, M. (2017). Five-Year Follow-Up After Laparoscopic Large Nerve Resection for Deep Infiltrating Sciatic Nerve Endometriosis. In *Journal of Minimally Invasive Gynecology* (Vol. 24, Issue 5, pp. 822–826). Elsevier BV. <https://doi.org/10.1016/j.jmig.2017.02.027>
- Stacy, J., Frawley, H., Powell, G., Goucke, R., & Pavy, T. (2012). Persistent pelvic pain: Rising to the challenge. In *Australian and New Zealand Journal of Obstetrics and Gynaecology* (Vol. 52, Issue 6, pp. 502–507). Wiley. <https://doi.org/10.1111/j.1479-828x.2012.01473.x>

- Valentine, L., & Deimling, T. (2018). Opioids and Alternatives in Female Chronic Pelvic Pain. In *Seminars in Reproductive Medicine* (Vol. 36, Issue 02, pp. 164–172). Georg Thieme Verlag KG. <https://doi.org/10.1055/s-0038-1676102>
- van OPHOVEN, A., POKUPIC, S., HEINECKE, A., & HERTLE, L. (2004). A PROSPECTIVE, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY OF AMITRIPTYLINE FOR THE TREATMENT OF INTERSTITIAL CYSTITIS. In *Journal of Urology* (Vol. 172, Issue 2, pp. 533–536). Ovid Technologies (Wolters Kluwer Health). <https://doi.org/10.1097/01.ju.0000132388.54703.4d>
- Abosamak, N. R., & Shahin, M. H. (2022). Beta 2 Receptor Agonists/Antagonists. In *StatPearls*. StatPearls Publishing.
- Abrams, P., & Andersson, K.-E. (2007). Muscarinic receptor antagonists for overactive bladder. In *BJU International* (Vol. 100, Issue 5, pp. 987–1006). Wiley. <https://doi.org/10.1111/j.1464-410x.2007.07205.x>
- Abrams, P., Andersson, K.-E., Buccafusco, J. J., Chapple, C., de Groat, W. C., Fryer, A. D., Kay, G., Laties, A., Nathanson, N. M., Pasricha, P. J., & Wein, A. J. (2006). Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. In *British Journal of Pharmacology* (Vol. 148, Issue 5, pp. 565–578). Wiley. <https://doi.org/10.1038/sj.bjp.0706780>
- Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., Van Kerrebroeck, P., Victor, A., & Wein, A. (2003). The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. In *Urology* (Vol. 61, Issue 1, pp. 37–49). Elsevier BV. [https://doi.org/10.1016/s0090-4295\(02\)02243-4](https://doi.org/10.1016/s0090-4295(02)02243-4)
- Alhayek, S., & Preuss, C. V. (2021). Beta 1 Receptors. In *StatPearls*. StatPearls Publishing.
- Arlandis, S., Bø, K., Cobussen-Boekhorst, H., Costantini, E., de Heide, M., Farag, F., Groen, J., Karavitakis, M., Lapitan, M. C., Manso, M., Arteaga, S. M., Nambiar, A. K., Riogh, A., O'Connor, E., Omar, M. I., Peyronnet, B., Phé, V., Sakalis, V. I., Sihra, N., Tzelves, L., ... Harding, C. K. (2022). European Association of Urology Guidelines on the Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 2: Underactive Bladder, Bladder Outlet Obstruction, and Nocturia. *European urology*, 82(1), 60–70. <https://doi.org/10.1016/j.eururo.2022.01.044>
- Bartoli, S., Aguzzi, G., & Tarricone, R. (2010). Impact on Quality of Life of Urinary Incontinence and Overactive Bladder: A Systematic Literature Review. In *Urology* (Vol. 75, Issue 3, pp. 491–500). Elsevier BV. <https://doi.org/10.1016/j.urology.2009.07.1325>
- Cetinel, B., & Onal, B. (2013). Rationale for the Use of Anticholinergic Agents in Overactive Bladder With Regard to Central Nervous System and Cardiovascular System Side Effects. *Korean Journal of Urology*, 54(12), 806–815.
- Chancellor, M., & Boone, T. (2012). Anticholinergics for overactive bladder therapy: central nervous system effects. *CNS neuroscience & therapeutics*, 18(2), 167–174. <https://doi.org/10.1111/j.1755-5949.2011.00248.x>
- Costello, M. (2011). The Use of Simulation in Medication Calculation Instruction. In *Nurse Educator* (Vol. 36, Issue 5, pp. 181–182). Ovid Technologies (Wolters Kluwer Health). <https://doi.org/10.1097/nne.0b013e3182297a1d>
- Dooley, Y., Kenton, K., Cao, G., Luke, A., Durazo-Arvizu, R., Kramer, H., & Brubaker, L. (2008). Urinary Incontinence Prevalence: Results From the National Health and Nutrition

- Examination Survey. In *Journal of Urology* (Vol. 179, Issue 2, pp. 656–661). Ovid Technologies (Wolters Kluwer Health). <https://doi.org/10.1016/j.juro.2007.09.081>
- Dmochowski R. R. (2021). Editorial. *Neurourology and urodynamics*, 40(5), 1077. <https://doi.org/10.1002/nau.24734>
- Dmochowski, R. R., Blaivas, J. M., Gormley, E. A., Juma, S., Karram, M. M., Lightner, D. J., Lubner, K. M., Rovner, E. S., Staskin, D. R., Winters, J. C., & Appell, R. A. (2010). Update of AUA Guideline on the Surgical Management of Female Stress Urinary Incontinence. In *Journal of Urology* (Vol. 183, Issue 5, pp. 1906–1914). Ovid Technologies (Wolters Kluwer Health). <https://doi.org/10.1016/j.juro.2010.02.2369>
- Dmochowski, R. R., Thai, S., Iglay, K., Enemchukwu, E., Tee, S., Varano, S., Girman, C., Radican, L., Mudd, P. N., Jr, & Poole, C. (2021). Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta-analysis. *Neurourology and urodynamics*, 40(1), 28–37. <https://doi.org/10.1002/nau.24536>
- Dumoulin, C., Cacciari, L. P., & Hay-Smith, E. J. C. (2018). Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. In *Cochrane Database of Systematic Reviews* (Vol. 2018, Issue 10). Wiley. <https://doi.org/10.1002/14651858.cd005654.pub4>
- Dumoulin, C., & Hay-Smith, J. (2010). Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. In C. Dumoulin (Ed.), *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.cd005654.pub2>
- Ganz, M. L., Smalarz, A. M., Krupski, T. L., Anger, J. T., Hu, J. C., Wittrup-Jensen, K. U., & Pashos, C. L. (2010). Economic Costs of Overactive Bladder in the United States. In *Urology* (Vol. 75, Issue 3, pp. 526–532.e18). Elsevier BV. <https://doi.org/10.1016/j.urology.2009.06.096>
- Gormley, E. A., Lightner, D. J., Burgio, K. L., Chai, T. C., Clemens, J. Q., Culkin, D. J., Das, A. K., Foster, H. E., Scarpero, H. M., Tessier, C. D., & Vasavada, S. P. (2012). Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. In *Journal of Urology* (Vol. 188, Issue 6S, pp. 2455–2463). Ovid Technologies (Wolters Kluwer Health). <https://doi.org/10.1016/j.juro.2012.09.079>
- Herderschee, R., Hay-Smith, E. J. C., Herbison, G. P., Roovers, J. P., & Heineman, M. J. (2011). Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women. In *Cochrane Database of Systematic Reviews*. Wiley. <https://doi.org/10.1002/14651858.cd009252>
- Herschorn, S., Barkin, J., Castro-Diaz, D., Frankel, J. M., Espuna-Pons, M., Gousse, A. E., Stölzel, M., Martin, N., Gunther, A., & Van Kerrebroeck, P. (2013). A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β_3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder. In *Urology* (Vol. 82, Issue 2, pp. 313–320). Elsevier BV. <https://doi.org/10.1016/j.urology.2013.02.077>
- Hong, C. T., Chan, L., Wu, D., Chen, W. T., & Chien, L. N. (2019). Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson's disease. *Parkinsonism & related disorders*, 65, 224–229. <https://doi.org/10.1016/j.parkreldis.2019.06.022>
- Huntley, J., Ostfeld, A. M., Taylor, J. O., Wallace, R. B., Blazer, D., Berkman, L. F., Evans, D. A., Kohout, J., Lemke, J. H., Scherr, P. A., & Korper, S. P. (1993). Established

- populations for epidemiologic studies of the elderly: Study design and methodology. In *Aging Clinical and Experimental Research* (Vol. 5, Issue 1, pp. 27–37). Springer Science and Business Media LLC. <https://doi.org/10.1007/bf03324123>
- Irwin, D. E., Milsom, I., Hunskaar, S., Reilly, K., Kopp, Z., Herschorn, S., Coyne, K., Kelleher, C., Hampel, C., Artibani, W., & Abrams, P. (2006). Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study. In *European Urology* (Vol. 50, Issue 6, pp. 1306–1315). Elsevier BV. <https://doi.org/10.1016/j.eururo.2006.09.019>
- Lightner, D. J., Gomelsky, A., Souter, L., & Vasavada, S. P. (2019). Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. In *Journal of Urology* (Vol. 202, Issue 3, pp. 558–563). Ovid Technologies (Wolters Kluwer Health). <https://doi.org/10.1097/ju.0000000000000309>
- Madhuvrata, P., Cody, J. D., Ellis, G., Herbison, G. P., & Hay-Smith, E. J. (2012). Which anticholinergic drug for overactive bladder symptoms in adults. *The Cochrane database of systematic reviews*, 1, CD005429. <https://doi.org/10.1002/14651858.CD005429.pub2>
- Nitti, V. W., Dmochowski, R., Herschorn, S., Sand, P., Thompson, C., Nardo, C., Yan, X., Haag-Molkenteller, C., & EMBARK Study Group (2013). OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. *The Journal of urology*, 189(6), 2186–2193. <https://doi.org/10.1016/j.juro.2012.12.022>
- Park, H. Y., Park, J. W., Song, H. J., Sohn, H. S., & Kwon, J. W. (2017). The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea. *PloS one*, 12(1), e0169463. <https://doi.org/10.1371/journal.pone.0169463>
- Rovner, E., Chai, T. C., Jacobs, S., Christ, G., Andersson, K. E., Efros, M., Nitti, V., Davies, K., McCullough, A. R., & Melman, A. (2020). Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. *Neurourology and urodynamics*, 39(2), 744–753. <https://doi.org/10.1002/nau.24272>
- Stewart, W., Van Rooyen, J., Cundiff, G., Abrams, P., Herzog, A., Corey, R., Hunt, T., & Wein, A. (2003). Prevalence and burden of overactive bladder in the United States. In *World Journal of Urology* (Vol. 20, Issue 6, pp. 327–336). Springer Science and Business Media LLC. <https://doi.org/10.1007/s00345-002-0301-4>
- Syan, R., Zhang, C. A., & Enemchukwu, E. A. (2020). Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients. In *Urology* (Vol. 142, pp. 81–86). Elsevier BV. <https://doi.org/10.1016/j.urology.2020.04.109>
- Welk, B., & McArthur, E. (2020). Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. *BJU international*, 126(1), 183–190. <https://doi.org/10.1111/bju.15040>

Cancer of the anus, anal canal, and anorectum - cancer stat facts. SEER. (n.d.). Retrieved June 22, 2022, from <https://seer.cancer.gov/statfacts/html/anus.html>

- Centers for Disease Control and Prevention. *Epidemiology and Prevention of Vaccine-Preventable Diseases*. Hall E., Wodi A.P., Hamborsky J., et al., eds. 14th ed. Washington, D.C. Public Health Foundation, 2021.
- Centers for Disease Control and Prevention. (2020, September 3). *Cancers associated with human papillomavirus, United States-2013–2017*. Centers for Disease Control and Prevention. Retrieved June 22, 2022, from <https://www.cdc.gov/cancer/uscs/about/data-briefs/no18-hpv-assoc-cancers-UnitedStates-2013-2017.htm>
- Centers for Disease Control and Prevention. (2021, January 25). *Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States*. Centers for Disease Control and Prevention. Retrieved June 22, 2022, from <https://www.cdc.gov/std/statistics/prevalence-2020-at-a-glance.htm>
- How many people are infected with HPV?* HPV Vaccine | How many are infected with HPV? (n.d.). Retrieved June 22, 2022, from <http://hpvaccine.co.za/how-many-are-infected.html>
- Iarc. (n.d.). *Human papillomaviruses*. IARC Publications Website. Retrieved June 22, 2022, from <https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Human-Papillomaviruses-2007>